Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of GS-248 for Raynaud's phenomenon in systemic sclerosis
2020-002081-13Phase 2Unknown
- Sponsor
- Gesynta Pharma
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Raynaud disease and systemic sclerosis (SSc) comparing GS-248 with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Status: unknown.
02
Drugs
vipoglanstat
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2020-002081-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002081-13.